Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)

Inclusion Criteria: * Patients with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE), or lupus erythematosus tumidus (LET) according to the Düsseldorf Classification 2004 (Kuhn and Ruzicka 2004) confirmed by histological analysis. * Women of childbearing potential with a negative pregnancy test at screening (urine test) and using a medically accepted contraceptive regimen (intra-uterine device, partner's vasectomy, \>3 months previous hormonal contraception (oestrogen plus gestagen pill, depot injections, or subcutaneous depot) combined with a barrier method (preservative, vaginal diaphragm, cervical cap, spermicide) during the study and for 8 weeks after the last UV exposure. * Women clinically sterile (post-menopausal, undergone hysterectomy or tubal ligation). * Actively cooperating to participate in the study, to follow the instructions of the investigator and to attend the centre at the agreed times. * Development of skin lesions any time under current systemic treatment if patient is receiving systemic medication for the treatment of CLE. * Signed informed consent form after the nature of the study has been fully explained. Exclusion Criteria: * Pregnancy or lactation and women with positive pregnancy test. * Known hypersensitivity or allergic contact reactions to components of the study agents. * Treatment with photosensitizing drugs. * Exposure to direct natural (sunlight) or artificial UV radiation on the back within 4 weeks prior to entering the study. * History of another photodermatosis, except polymorph light eruption (PLE). * Any current known skin malignancy or any history of skin malignancy within the previous 5 years or Xeroderma pigmentosum. * Initiation or change in the dose of any current systemic medication for the treatment of CLE within 8 weeks prior to standardized photoprovocation. * Local therapy for the treatment of CLE within two weeks prior to standardized photoprovocation at the back of the patient * Acute exacerbation of CLE skin disease within 2 weeks prior to entering the study. * Acute illness within 7 days prior to phototesting or major illness including infection or hospitalization within 1 month of study entry. * Anti-dsDNA (RIA) \> 7 U/ml and/or at least one of the following criteria: * Serositis: pleuritis or pericarditis documented by electrocardiogram or rub or evidence of pericardial effusion; * Renal disorder: proteinuria greater than 0.5 g/d or greater than 3+, or cellular casts; * Neurologic disorder: seizures or psychosis without other cause. * Patients with a documented HIV and/or hepatitis B or C infection. * Any medical condition, which would place the subject at undue risk of, or make it unlikely that follow-up-measurements could be obtained